Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | B. Han, T. Chu, J. Qian, B. Yan, Y. Zhang, Q. Chang | ||||||||||||
Title | Preliminary Results of Second Generation ALK Inhibitor PLB1003: A Phase La Study | ||||||||||||
|
|||||||||||||
URL | https://www.jto.org/article/S1556-0864(19)32058-1/abstract | ||||||||||||
Abstract Text | Journal of Thoracic Oncology, Volume 14, Issue 10, S651 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PLB1003 | PLB 1003|PLB-1003 | ALK Inhibitor 32 | PLB1003 is a small molecule inhibitor of Alk that potentially leads to tumor growth inhibition (Journal of Thoracic Oncology, Volume 14, Issue 10, S651). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK rearrange | lung non-small cell carcinoma | predicted - sensitive | PLB1003 | Phase I | Actionable | In a Phase Ia trial, PLB1003 demonstrated safety and preliminary efficacy, resulted in a disease control rate of 86% (12/14, 10 partial response, 2 stable disease) in patients with ALK-rearranged non-small cell lung cancer who progressed on or did not tolerate previous treatment (Journal of Thoracic Oncology, Volume 14, Issue 10, S651). | detail... |